These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36939478)

  • 1. Rh alloimmunization following transfusion of one apheresis platelet unit.
    Abels E; Binns TC; Jacobs JW; Stendahl K; Tormey CA
    Transfusion; 2023 Mar; 63(3):656-657. PubMed ID: 36939478
    [No Abstract]   [Full Text] [Related]  

  • 2. Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study.
    Cid J; Lozano M; Ziman A; West KA; O'Brien KL; Murphy MF; Wendel S; Vázquez A; Ortín X; Hervig TA; Delaney M; Flegel WA; Yazer MH;
    Br J Haematol; 2015 Feb; 168(4):598-603. PubMed ID: 25283094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive anti-C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series.
    Sostin N; Ross R; Balbuena-Merle R; Hendrickson JE; Tormey CA
    J Clin Apher; 2020 Jun; 35(3):224-226. PubMed ID: 32110829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
    Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
    Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
    Trial to Reduce Alloimmunization to Platelets Study Group
    N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D+ platelet transfusions in D- patients: cause for concern?
    Bartley AN; Carpenter JB; Berg MP
    Immunohematology; 2009; 25(1):5-8. PubMed ID: 19856725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles?
    Kitazawa J; Nollet K; Morioka H; Tanaka K; Inomata M; Kubuki Y; Ohto H
    Vox Sang; 2011 May; 100(4):395-400. PubMed ID: 21029111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
    Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
    Front Immunol; 2018; 9():1251. PubMed ID: 29951051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
    Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
    Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The perils of platelet transfusions.
    Kruskall MS
    N Engl J Med; 1997 Dec; 337(26):1914-5. PubMed ID: 9407160
    [No Abstract]   [Full Text] [Related]  

  • 12. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
    Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
    Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigation strategies for anti-D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: a survey of NCCN
    Poston JN; Sugalski J; Gernsheimer TB; Marc Stewart F; Pagano MB
    Vox Sang; 2020 May; 115(4):334-338. PubMed ID: 32080868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Platelet transfusion and immunization anti-Rh1: implication for immunoprophylaxis].
    Chambost H
    Transfus Clin Biol; 2014 Nov; 21(4-5):210-5. PubMed ID: 25282489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of single donor platelets.
    Kirkley SA; Blumberg N
    Blood Rev; 1994 Sep; 8(3):142-7. PubMed ID: 7819816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion of apheresis platelets and ABO groups.
    Vox Sang; 2005 Apr; 88(3):207-21. PubMed ID: 15787735
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of Rh(D) alloimmunization after transfusion of platelets from D+ donors to D- recipients.
    Cid J; Lozano M
    Transfusion; 2005 Mar; 45(3):453; author reply 453-4. PubMed ID: 15752167
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet component transfusion and alloimmunization: Where do we stand?
    Moncharmont P
    Transfus Clin Biol; 2018 Sep; 25(3):172-178. PubMed ID: 29478960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INTERCEPT pathogen-reduced platelets are not associated with higher rates of alloimmunization with (or without) clinical refractoriness in published studies.
    Benjamin RJ; Corash L; Norris PJ
    Transfusion; 2020 Apr; 60(4):881-882. PubMed ID: 32246477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.